Hatice Ayyıldız Sevim

Dr. Hatice Ayyıldız Sevim

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HSHatice Ayyıldız Sevim
Hatice Ayyıldız Sevim
KYKadriye Bir Yücel
Kadriye Bir Yücel
GUGalip Uyar
Galip Uyar
HŞHayriye Şahinli
Hayriye Şahinli
Background: Biliary drainage is a key component of palliative management in patients with malignant biliary obstruction. In cases where endoscopic approaches are unsuccessful or cannot be performed, percutaneous transhepatic biliary drainage (PTBD) represents an established alternative for achieving biliary decompression. The C-reactive protein–albumin–lymphocyte (CALLY) index combines inflammatory, nutritional, and immune-related parameters into a single marker, while the modified Glasgow Prognostic Score (mGPS), based on C-reactive protein and albumin concentrations, reflects the systemic inflammatory status of the patient. This study aimed to evaluate the prognostic value of the preprocedural CALLY index and mGPS in predicting 30-day mortality among patients with advanced malignant biliary obstruction undergoing palliative PTBD. Methods: This single-center retrospective study was conducted in a total of 179 patients who underwent palliative PTBD for malignant biliary obstruction at Ankara Etlik City Hospital between December 2022 and June 2025. Results: The 30-day mortality rate was 25.1%. The cut-off value for CALLY was determined as 67 based on receiver operating characteristic (ROC) curve analysis, and mGPS was categorized as 0–1 versus 2. In univariable Cox regression analyses, pancreaticobiliary tumor type, mGPS = 2, and CALLY < 67 were associated with early mortality. In multivariable Cox analysis, CALLY ≥ 67 was independently associated with a reduced risk of 30-day mortality, whereas pancreaticobiliary tumor type was independently associated with an increased risk. In the CALLY–mGPS risk stratification, 30-day mortality rates were 8.0%, 13.5%, and 44.1% in the low-, intermediate-, and high-risk groups, respectively. Conclusions: In this retrospective cohort, preprocedural inflammation- and nutrition-based markers were found to be associated with early mortality in patients with malignant biliary obstruction undergoing PTBD. Accordingly, risk stratification using readily available parameters such as CALLY and mGPS appears feasible in the preprocedural setting. The CALLY–mGPS-based approach may provide a practical framework for clinical risk assessment; however, prospective multicenter validation, including tumor-specific subgroup analyses, is warranted.

17 June 2026 in Medicina
Verified
Journal Article
Open access
PDF file
SÇselahattin çelik
selahattin çelik
SKSalih Karatlı
Salih Karatlı
MAMEHMETCAN ATAK
MEHMETCAN ATAK
HSHatice Ayyıldız Sevim
Hatice Ayyıldız Sevim
GİGökşen İnanç İmamoğlu
Gökşen İnanç İmamoğlu
SRSamed Rahatlı
Samed Rahatlı
Background and Objectives: Quality of life (QoL) has become an essential outcome in patients with metastatic prostate cancer, particularly in the era of androgen receptor (AR)-targeted therapies. Although these agents improve survival, their differential impact on QoL and the role of psychological factors remain incompletely understood. This study aimed to evaluate QoL, functional outcomes, and psychological status, and to identify factors associated with poor QoL in a real-world cohort. Materials and Methods: This prospective cross-sectional, single-center observational study included 130 patients with metastatic prostate cancer receiving AR-targeted therapies (abiraterone, enzalutamide, or apalutamide/darolutamide). QoL was assessed using the EORTC QLQ-C30 questionnaire, and psychological status was evaluated using the Hospital Anxiety and Depression Scale (HADS). Patients were stratified according to treatment groups, and comparisons were performed using appropriate statistical tests. Logistic regression analyses were conducted to determine factors independently associated with poor QoL. Results: Exploratory differences in global QoL were observed among treatment groups (p = 0.007), with lower global QoL scores in the abiraterone group and numerically higher emotional and cognitive functioning scores in the enzalutamide group. Symptom analysis demonstrated higher nausea/vomiting scores in the abiraterone group (p = 0.022), whereas other symptom domains were comparable across treatment groups. In multivariable analysis, anxiety (odds ratio [OR]: 6.62) and depression (OR: 3.40) were independently associated with poor QoL, while treatment type was not independently associated with poor QoL after multivariable adjustment. Conclusions: Although unadjusted QoL scores differed across AR-targeted therapy groups, psychological factors—particularly anxiety and depression—were significantly associated with poorer QoL in patients with metastatic prostate cancer. These findings highlight the importance of integrating routine psychosocial assessment and supportive care strategies into clinical practice to optimize patient-centered outcomes. However, given the cross-sectional and exploratory nature of the study, the findings should be interpreted cautiously.

1 September 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
SÇselahattin çelik
selahattin çelik
SKSalih Karatlı
Salih Karatlı
EZEsra Zeynelgil
Esra Zeynelgil
HSHatice Ayyıldız Sevim
Hatice Ayyıldız Sevim
TETülay Eren
Tülay Eren
Background and Objectives: Pathologic stage IIA (T3N0M0) colon cancer represents a heterogeneous subgroup of stage II disease with variable recurrence risk despite similar TNM staging. Although several clinicopathological high-risk features are incorporated into current treatment guidelines, the independent prognostic significance of emergency surgery remains incompletely understood. This study aimed to identify clinicopathological predictors of postoperative recurrence, with particular emphasis on the prognostic impact of emergency surgery. Materials and Methods: This retrospective single-center cohort study included 118 patients with pathologic T3N0M0 colon adenocarcinoma who underwent curative-intent surgery. Demographic, clinicopathological, treatment, and follow-up data were analyzed. Univariable and multivariable logistic regression analyses were performed to identify independent predictors of recurrence. Because adjuvant chemotherapy was not randomly assigned, a sensitivity analysis including adjuvant chemotherapy was conducted to address confounding by indication. Disease-free survival (DFS) was evaluated using the Kaplan–Meier method. Results: During follow-up, recurrence occurred in 15 patients (12.7%). Patients with recurrence underwent emergency surgery significantly more frequently than those without recurrence (60.0% vs. 20.4%, p = 0.003). Perineural invasion and adjuvant chemotherapy were associated with recurrence in univariable analyses. In the primary multivariable model, emergency surgery remained an independent predictor of recurrence (OR 5.508, 95% CI 1.726–17.576; p = 0.004), whereas perineural invasion showed only borderline significance. In the sensitivity analysis, emergency surgery remained independently associated with recurrence (OR 4.079, 95% CI 1.207–13.779; p = 0.024), while adjuvant chemotherapy was no longer independently associated with recurrence. Kaplan–Meier analysis demonstrated significantly shorter DFS among patients undergoing emergency surgery (log-rank p = 0.002). Conclusions: Among patients with pathologic T3N0M0 colon cancer, the need for emergency surgery was associated with a higher risk of recurrence after adjustment for other clinicopathological factors. Emergency presentation may therefore serve as an additional marker for identifying patients at increased postoperative risk. Further prospective multicenter research is needed to confirm this association and to explore its potential value when combined with molecular biomarkers for individualized postoperative management.

6 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HSHatice Ayyıldız Sevim
Hatice Ayyıldız Sevim
GUGalip Uyar
Galip Uyar
GAGÜNER AKGÜNER
GÜNER AKGÜNER
HŞHayriye Şahinli
Hayriye Şahinli
Background: The comparative prognostic value of the Endothelial Activation and Stress Index (EASIX) and the Inflammatory Prognostic Index (IPI) in extensive-stage small-cell lung cancer remains unclear. This study aimed to compare the prognostic value of EASIX and IPI and assess their contribution beyond established clinical factors. Methods: This retrospective single-center study included 129 patients with de novo extensive-stage small-cell lung cancer who initiated first-line systemic therapy between December 2022 and October 2025. Pretreatment EASIX and IPI values were analyzed as log2-transformed continuous variables in multivariable Cox models. Overall survival was the primary outcome, and first-line progression-free survival was the secondary outcome. Results: During a median follow-up of 26.91 months, 116 deaths and 123 progression-or-death events occurred. Each doubling of the EASIX value was independently associated with a higher hazard of death (adjusted hazard ratio, 1.14; 95% confidence interval, 1.01–1.28; p = 0.019), whereas IPI was not independently associated with overall survival. Neither index was independently associated with first-line progression-free survival. Adding EASIX to the clinical model improved model fit and increased the C-index from 0.619 to 0.650, whereas IPI provided no additional prognostic contribution. Conclusions: EASIX may provide prognostic information beyond established clinical factors for overall survival in extensive-stage small-cell lung cancer. These findings warrant validation in larger multicenter cohorts.

14 April 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
HSHatice Ayyıldız Sevim
Hatice Ayyıldız Sevim
MAMehmetcan Atak
Mehmetcan Atak
ZDZeynep Altundağ Derin
Zeynep Altundağ Derin
SÇSelahattin Çelik
Selahattin Çelik
IGİsMail Burak Gültekin
İsMail Burak Gültekin
DYDoğan Yazılıtaş
Doğan Yazılıtaş
Objective: To evaluate the predictive value of the mean platelet volume–to–albumin (MPV/Alb) ratio for pathological complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) treated with neoadjuvant chemotherapy (NACT). Methods: In this retrospective single-center study, 139 consecutive patients with HER2-positive breast cancer who received dual anti-HER2 therapy combined with anthracycline- and taxane-based neoadjuvant chemotherapy between December 2022 and February 2025 were included. Clinicopathological variables, immuno-inflammatory parameters, and the MPV/Alb ratio were analyzed. Predictors of pCR were assessed using univariable and multivariable logistic regression. Discriminative performance and an optimal cut-off for MPV/Alb were determined by receiver operating characteristic (ROC) analysis. Results: The median age was 50 years (range, 26–79), and pCR was achieved in 54.7% of patients. On univariable analyses, estrogen receptor (ER) status, progesterone receptor (PR) status, and MPV/Alb were associated with pCR. In multivariable analysis, only MPV/Alb remained an independent predictor of pCR ( p = 0.012; odds ratio [OR], 0.388; 95% confidence interval [CI], 0.185–0.813). ROC analysis identified an optimal MPV/Alb cutoff of 2.32 (AUC 0.626; 95% CI 0.535–0.720; p = 0.048), yielding 64.5% sensitivity and 58.7% specificity. Conclusions: The MPV/Alb ratio may serve as an independent predictor of pCR in HER2-positive BC undergoing NACT. As a readily obtainable, low-cost composite derived from routine laboratory tests, MPV/Alb could aid risk stratification and treatment decision-making in clinical practice.

28 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
HSHatice Ayyıldız Sevim
Hatice Ayyıldız Sevim
HŞHayriye Şahinli
Hayriye Şahinli
GUGalip Uyar
Galip Uyar
SÇselahattin çelik
selahattin çelik
SKSalih Karatlı
Salih Karatlı
GİGökşen İnanç İmamoğlu
Gökşen İnanç İmamoğlu
Background and Objectives: The effect of bevacizumab on the morphology of non-tumoral organs remains unclear. We evaluated computed tomography (CT)- derived treatment-emergent pancreatic volume loss and examined its association with progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer receiving bevacizumab. Materials and Methods: This single-center retrospective study included 105 patients treated at Ankara Etlik City Hospital who had evaluable paired contrast-enhanced CT scans obtained before and during therapy. Pancreatic volume was measured on CT, and percentage volume loss was calculated. Clinical, laboratory, radiological, and survival data were retrospectively reviewed. Results: Mean pancreatic volume declined from 89.9 ± 6.1 mL before treatment to 83.6 ± 5.1 mL during therapy (p < 0.001). Albumin levels and platelet counts also decreased, whereas amylase, hemoglobin, and the neutrophil-to-lymphocyte ratio remained largely unchanged. In the main multivariable models, each 1% increase in pancreatic volume loss was associated with worse bevacizumab-line PFS (HR 1.06, 95% CI 1.02–1.10; p = 0.032) and OS (HR 1.08, 95% CI 1.01–1.15; p = 0.041). Percentage change in albumin was independently associated with both endpoints. Sensitivity analyses supported a more consistent association of pancreatic volume loss with PFS than with OS. Conclusions: Pancreatic volume decreased during bevacizumab-containing therapy. Greater pancreatic volume loss was associated with shorter PFS and OS; however, the association was more consistent for PFS. Prospective studies are needed to validate these findings and determine their clinical relevance.